GSK and Wave

RNA editing to change disease treatment

GSK and Wave
Close Video

Scroll to explore

Ahead Together in  genetics/genomics/vaccines/medicines/innovation

How our R&D approach helps us get Ahead Together

We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.

We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.

There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.

Tony Wood

Tony Wood

Chief Scientific Officer

  • Our R&D investment in 2023

  • Major business development deals in 2023

  • Vaccines and medicines in the pipeline

  • Phase I programmes started in 2023


Watch how we innovate



We created the Laboratory for Genomics Research with UCSF and UC Berkeley to advance genomic research and improve drug discovery

09 January 2023

Ahead of Disease Together

The pillars of our innovation

Scientist Testing Biological Samples cover

Partnerships that matter

Equipment Assembly Respiratory Medicine

How we apply technologies

Exterior of R&D Campus, GSK Stevenage

Our R&D locations

pinch icon

Spotlight on GSK innovation

A vaccine manufacturing production line in action

Financial Times

Breakthroughs in vaccine innovation are helping to protect more lives

Read on the FT
Woman studying scans on a computer


Can cutting-edge tech help battle neurodegenerative diseases?

Read on the FT
scientist working in a lab

Financial Times

Can you hear me? HIV community tells industry the struggle is not over

Read on the FT

Therapeutic areas

​The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, respiratory/immunology, and oncology. We remain open to opportunities outside these core areas where the science aligns with our strategic approach.

Innovation events and conferences

Hear from industry experts, explore the latest breakthroughs and network with us.